1.        2005/1-2007/12：国家自然科学基金青年项目：内源性硫化氢作为心脏功能调节新的气体信号分子的研究。项目负责人：23万元。项目批准号：30400151

2.        2006/6-2011/6：973：小分子生物活性物质在血管损伤性疾病发病中的作用研究。第七课题组骨干： 29.8万。项目批准号：2006CB503807

3.        2009/1-2014/12：973：畜禽肌肉和脂肪发育的分子调控机制研究。第三课题组骨干：20万。项目批准号：2009CB941603

4.        2010/1-2010/12：国家自然科学基金面上项目：脂肪源的硫化氢调节胰岛素抵抗的研究。项目负责人：8万元。项目批准号：30971084

5.        2012/1-2015/12：国家自然科学基金面上项目：硫化氢作为血管周脂肪组织源血管舒张因子参与高血压发病的机制。项目负责人：58万元。项目编号：81170235

6.        2012/6-2016/12：973: 环境代谢因素致高血压机制及其干预措施的研究。第六课题组骨干：72万。项目批准号：2012CB517806

7.        2015/1-2018/12: 国家自然科学基金面上项目：硫化氢拮抗高同型半胱氨酸诱导的动脉粥样硬化的蛋白质亚硝基化/硫氢化修饰机制。项目负责人：73万元。项目编号：81470552.

8.        2016/1-2018/12：北京市自然科学基金面上项目：LncVSM-人血管平滑肌特异表达的LncRNA在高血压发病中的机制研究。项目负责人：18万元。项目编号：7162093.

9.        2017/1-2020/12：国家自然科学基金面上项目：平滑肌特异性表达的长链非编码RNA - LncVSM诱发高血压血管平滑肌表型转换的机制。项目负责人：62万元(直接经费)。项目编号：81670379.

10.    2019/1-2022/12：国家自然科学基金面上项目：内源性CSE/H2S系统促进LKB1硫氢化调节CD4T细胞分化参与高血压发病。项目负责人：57万元(直接经费)。项目编号：81870318.

1.        Xu W, Cui C, Cui C, Chen Z, Zhang H, CuiQ, Xu G, Fan J, Han Y, Tang L, Targher G, Byrne CD, Zheng MH*, Yang L*, Cai J*,Geng B*. Hepatocellular Cystathionine gamma lyase/Hydrogen sulfideAttenuates Non-Alcoholic Fatty Liver Disease by Activating Farnesoid X Receptor.Hepatology 2022. 76:1794-1810

2.        Lin Q, Geng B*. The Role of HydrogenSulfide in Plaque Stability. Antioxidants (Basel). 2022;11:2356.

3.        Liu X, Chen Z, Li S, Jin L, Cui X, Cui C,Deng Y, Gao Q, Fan L, Niu Y, Wang W, Cui C, Zhong J, Cui Q*, Geng B*,Cai J*. Pre-miRNA Hsa-Let-7a-2: a Novel Intracellular Partner of Angiotensin IIType 2 Receptor Negatively Regulating its Signals. International Journal ofBiological Sciences 2022;18(8):3237-3250.

4.        Jin R, Yang R, Cui C, Zhang H, Cai J, GengB*, Chen Z*. Ferroptosis due to Cystathionine gammaLyase/Hydrogen Sulfide Downregulation Under High Hydrostatic PressureExacerbates VSMC Dysfunction. Front Cell Dev Biol 2022;10:829316.

5.        Chen Z, Ouyang C, Zhang H, Gu Y, Deng Y,Du C, Cui C, Li S, Wang W, Kong W, Chen J*, Cai J*, Geng B*. Vascularsmooth muscle cell-derived hydrogen sulfide promotes atherosclerotic plaquestability via TFEB (transcription factor EB)-mediated autophagy. Autophagy2022:18: 2270-2287.

6.        Niu Y#, Du C#, Cui C, Zhang H, Deng Y, CaiJ, Chen Z*,Geng B*. Norswertianolin Promotes Cystathionine gamma-LyaseActivity and Attenuates Renal Ischemia/Reperfusion Injury and Hypertension. FrontPharmacol. 2021;12:677212.

7.        Deng Y, Li S, Chen Z, Wang W, Geng B*,CaiJ*. Mdivi-1, a mitochondrial fission inhibitor, reduces angiotensin-II- inducedhypertension by mediating VSMC phenotypic switch. Biomed Pharmacother.2021;140:111689.

8.        Jiang S#, Xu W#, Chen Z, Cui C, Fan X, CaiJ, Gong Y*,Geng B*. Hydrogen sulphide reduceshyperhomocysteinaemia-induced endothelial ER stress by sulfhydrating proteindisulphide isomerase to attenuate atherosclerosis. J Cell Mol Med.2021;25:3437-3448.

9.        Liao F, Zhu Z, Xiao C, Yuan J, Geng B*,HuJ*. Hydrogen sulfide inhibits calcium and phosphorus loss after fracture bynegatively regulating glucocorticoid/glucocorticoid receptor alpha. Life Sci.2021;274:119363.

10.    Chen Z, Zhang H, Bai Y, Cui C, Li S, WangW, Deng Y, Gao Q, Wang L, Qi W, Zhang L, Yang Y, Geng B*, Cai J*. Single cell transcriptomic analysis identifies novel vascularsmooth muscle subsets under high hydrostatic pressure. Sci China Life Sci2021; 64: 1677-1690

11.   Cui C#, Fan J#, Zeng Q#, Cai J#, Chen Y,Chen Z, Wang W, Li SY, Cui Q, Yang J, Tang C, Xu G*, Cai J*, Geng B*.CD4(+) T-Cell Endogenous Cystathionine gamma Lyase-Hydrogen Sulfide AttenuatesHypertension by Sulfhydrating Liver Kinase B1 to Promote T Regulatory CellDifferentiation and Proliferation. Circulation. 2020; 142:1752-1769.

12.    Xiang R#, Chen J#, LiS#, Yan H, Meng Y, Cai J, Cui Q, Yang Y, Xu M, Geng B* and Yang J*.VSMC-Specific Deletion of FAM3A Attenuated Ang II-Promoted Hypertension andCardiovascular Hypertrophy. Circ Res. 2020;126:1746-1759.